Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Baxter
Harvard Business School
McKinsey

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Momelotinib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Momelotinib?

Momelotinib is an investigational drug.

There have been 14 clinical trials for Momelotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Polycythemia, Thrombocytosis, and Thrombocythemia, Essential. The leading clinical trial sponsors are Gilead Sciences, Sierra Oncology, Inc., and Fred Hutchinson Cancer Research Center.

There are twenty-seven US patents protecting this investigational drug and three hundred and one international patents.

Recent Clinical Trials for Momelotinib
TitleSponsorPhase
A Phase 3 Study Comparing the Activity of Momelotinib in Symptomatic and Anemic Myelofibrosis Patients Versus DanazolSierra Oncology, Inc.Phase 3
Extended Access of Momelotinib in Adults With MyelofibrosisGilead SciencesPhase 2
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Gilead SciencesPhase 2

See all Momelotinib clinical trials

Clinical Trial Summary for Momelotinib

Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib

See all Momelotinib clinical trials

US Patents for Momelotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Momelotinib   Start Trial Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Momelotinib   Start Trial Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Start Trial
Momelotinib   Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Momelotinib   Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Momelotinib   Start Trial Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Momelotinib   Start Trial Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Momelotinib   Start Trial Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Momelotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Momelotinib Argentina 096246 2033-05-09   Start Trial
Momelotinib Australia 2014262622 2033-05-09   Start Trial
Momelotinib Brazil 112015028017 2033-05-09   Start Trial
Momelotinib Canada 2911408 2033-05-09   Start Trial
Momelotinib Chile 2015003280 2033-05-09   Start Trial
Momelotinib China 105324379 2033-05-09   Start Trial
Momelotinib Costa Rica 20150639 2033-05-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
McKesson
Merck
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.